

## PERFORMANCE IN DELIVERING CLINICAL RESEARCH – Q1 (2022/23)

REC Number	IRAS Number	Project Title	Target Number of Patients Agreed?	Minimum Number of Patients Agreed	Maximum Number of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason for Closure of Trial
20/EE/0031	275993	PACIFIC Stroke - 19766 - Non-cardioembolic ischaemic stroke	Number Agreed	1	1	Date Agreed	02/08/2021	1	21/08/2021	1	Recruitment Finished
18/LO/0448	241283	CALDOSE - 1	Number Agreed	2	2	Date Agreed	22/01/2020	2	31/08/2021	2	Recruitment Finished
21/YH/0097	298529	4734 STEP10 semaglutide s.c.in subjects with obesity and prediabetes	Number Agreed	8	8	Date Agreed	27/12/2021	11	13/12/2021	11	Recruitment Finished
19/SW/0041	260477	Pembrolizumab + Lenvatinib verses Docetaxel in 2L+ NSCLC (LEAP-008)	Number Agreed	4	4	Date Agreed	28/02/2022	1	15/02/2022	1	Recruitment Finished
21/LO/0193	294285	1366-0005 BI 685509 Diabetic KD	Number Agreed	2	2	Date Agreed	01/03/2022	2	08/03/2022	2	Recruitment Finished
21/WS/0053	1003692	Advance SC	Number Agreed	1	1	Date Agreed	01/01/2021	2	31/03/2022	2	Recruitment Finished
20/LO/0957	276634	Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice	Number Agreed	2	2	Date Agreed	30/04/2022	4	22/06/2022	4	Recruitment Finished